ReviewApplied microbiology and biotechnology2026
Engineering of ω-transaminases for advanced applications.
Review in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ω-Transaminases (ω-TAs) are well-established biocatalysts for the asymmetric synthesis of chiral amines, yet their broader application remains limited by challenges related to activity, substrate scope, equilibrium constraints in asymmetric synthesis, and process compatibility e.g. solvent tolerance. In recent years, research has shifted from enzyme discovery toward targeted development strategies aimed at addressing these limitations. This review summarizes recent advances in ω-transaminase development, with a focus on protein engineering and process-level optimization. Structure-guided and semi-rational mutagenesis approaches continue to provide robust, incremental improvements, while multi-site, activity-driven engineering has proven effective for challenging substrates such as β- and γ-amino acids or bulky amines. Emerging AI- and AlphaFold-assisted workflows increasingly support rational enzyme design by reducing experimental efforts. Beyond enzyme sequence optimization, reaction engineering, multienzyme cascades, and process intensification strategies play a crucial role in improving overall performance and scalability. Genome mining and discovery efforts are briefly discussed as supporting tools for expanding the ω-transaminase toolbox. Overall, studies in the last years show that successful ω-transaminase development relies more and more on integrated approaches combining enzyme engineering with intelligent process design, rather than on isolated optimization strategies. KEY POINTS: •The state-of-the-art status of ω-TA development is presented. •The shift from enzyme discovery to substrate-based optimization is highlighted. •Modern reaction conditions for more environmentally friendly synthesis are reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.